SCI Abstract

search
+
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Response and progression criteria are necessary for any malignancy to standa...
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Accumulating evidence suggests that blinatumomab (a CD3-CD19 bispecific T-ce...
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Anemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Despite the considerable effort to characterize the genomic landscape of chronic lymphocytic leukemia (CLL), published dat...
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective the...
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
CBF-AMLs, which account for approximately 12–15% of all AML cases, involve c...
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or re...
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
Multiple myeloma (MM) is a hematological malignancy whose curability is greatly challenged by recurrent patient relapses a...
Bispecific antibodies in the treatment of multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with...
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP2...
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy f...
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations ...
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term...
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on t...
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Competing interests MS reports receiving funding from BeiGene paid to Fred...
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
Multiple myeloma (MM) is a plasma cell neoplasm (PCN) [1]. Sensitive and accurate identification of g...
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
TP53 mutations (TP53Mut) define the most rapidly fatal AML subtype [1, 2] (Supplementary Fig. S1A). We used AML datasets (...
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients
Nucleoporin 98 (NUP98, chromosome 11p15) fusion oncoproteins also called NUP98 rearrangements (NUP98r...
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
BCL-2, a crucial regulator of the mitochondrial apoptotic pathway, maintains myeloblast survival by s...
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients
CAR-T cell therapy has led to a significant advance in the treatment of refractory/relapsed diffuse l...
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). A...
Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
It is well-established that most patients with systemic light chain (AL) amyloidosis have multi-organ involvement and are ...
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Survey of interpretation practices of unbalanced MYC break-apart resultsFifty-four responses were obtained to the survey q...
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Competing interests EM and VG have no conflicts of interest to disclose. S...
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marro...
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Nucleophosmin 1 (NPM1) is one of the most frequently mutated genes (~30% of cases) in acute myeloid l...
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (...
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primari...
Load More
format_indent_increase